Cilomilast

Drug Profile

Cilomilast

Alternative Names: AL-38583; Ariflo; SB 207499; SKB 207499

Latest Information Update: 14 Mar 2012

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Alcon; GlaxoSmithKline
  • Class Antibronchitics; Carboxylic acids; Nitriles; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease; Dry eyes; Ocular inflammation

Most Recent Events

  • 14 Mar 2012 Discontinued - Phase-II for Dry eyes in USA (Ophthalmic)
  • 14 Mar 2012 Discontinued - Phase-II for Ocular inflammation in USA (Ophthalmic)
  • 14 Mar 2012 Discontinued - Phase-III for Chronic obstructive pulmonary disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top